Greggs boss: 'No doubt’ weight loss jabs are impacting business
The rise of the weight-loss jab is forcing Greggs into a healthier corner
The boss of Greggs has said there is “no doubt” appetite-suppressing medication is having an impact on the bakery chain’s business as it introduces healthier options on its menu.
Chief executive Roisin Currie, who is originally from Glasgow, said: “What we’ve been seeing is people are looking for smaller portions, people are looking for information on areas such as protein and fibre, and therefore we’re making sure that in the breadth of our range we can offer those choices to customers.”
However, she highlighted this was not only due to the rise of GLP-1s, a class of medications that mimic the hormone which suppresses appetite, but also a “broader health trend” emerging.
This year Greggs, which has around 300 branches in Scotland and is best known for its baked goods, unveiled new healthier products to tap into this trend.
It has sold half a million egg pots since adding them to its range in the autumn and the chain this week launched an overnight oats product with seeds and dried fruit.
However, hot snacks also performed well, with 1.3 million hot food items sold each week on average in 2025.
On Thursday, the company reported that total sales jumped by 7.4% over the three months to December 27, despite a challenging market, but like-for-like sales for the full year increased by 2.4%, less than half the growth for 2024.
Comments
Want to join the conversation? Please or to comment on this article.